<code id='4378205CA2'></code><style id='4378205CA2'></style>
    • <acronym id='4378205CA2'></acronym>
      <center id='4378205CA2'><center id='4378205CA2'><tfoot id='4378205CA2'></tfoot></center><abbr id='4378205CA2'><dir id='4378205CA2'><tfoot id='4378205CA2'></tfoot><noframes id='4378205CA2'>

    • <optgroup id='4378205CA2'><strike id='4378205CA2'><sup id='4378205CA2'></sup></strike><code id='4378205CA2'></code></optgroup>
        1. <b id='4378205CA2'><label id='4378205CA2'><select id='4378205CA2'><dt id='4378205CA2'><span id='4378205CA2'></span></dt></select></label></b><u id='4378205CA2'></u>
          <i id='4378205CA2'><strike id='4378205CA2'><tt id='4378205CA2'><pre id='4378205CA2'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          hotspot

          author:explore    - browse:868
          Allergan, Dom Smith/STAT

          It wasn’t supposed to work out this way for Brent Saunders.

          Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

          advertisement

          As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus